

ONCOSEC MEDICAL Inc
 Form 4
 March 11, 2014

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 MAIDA ANTHONY E III

(Last) (First) (Middle)

C/O ONCOSEC MEDICAL
 INCORPORATED, 9810
 SUMMERS RIDGE RD SUITE 110

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

ONCOSEC MEDICAL Inc [ONCS]

3. Date of Earliest Transaction
 (Month/Day/Year)

03/07/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) | | |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|-----|-------|
| | | | | (A) or (D) | Code | V | Amount | (D) | Price |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative | 2. Conversion | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if | 4. Transaction | 5. Number of Derivative | 6. Date Exercisable and Expiration Date | 7. Title and Amount Underlying Securities |
|------------------------|---------------|--------------------------------------|-------------------------------|----------------|-------------------------|---|---|
|------------------------|---------------|--------------------------------------|-------------------------------|----------------|-------------------------|---|---|

Edgar Filing: ONCOSEC MEDICAL Inc - Form 4

| Security (Instr. 3) | or Exercise Price of Derivative Security | any (Month/Day/Year) | Code (Instr. 8) | Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | (Month/Day/Year) | (Instr. 3 and 4) | | | | |
|-----------------------------|--|----------------------|-----------------|---|------------------|------------------|---------------------------|-----------------|--------------|----------------------|
| | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount Number Shares |
| Stock Option (Right to Buy) | \$ 0.805 | 03/07/2014 | A | | 250,000 | | 03/07/2014 ⁽¹⁾ | 03/07/2024 | Common Stock | 250,000 |

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

MAIDA ANTHONY E III
 C/O ONCOSEC MEDICAL INCORPORATED
 9810 SUMMERS RIDGE RD SUITE 110
 SAN DIEGO, CA 92121

X

Signatures

/s/ Anthony Maida 03/11/2014

__Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) (1) Vesting occurs in four equal quarterly increments, with the first vesting occurring on March 7, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. nt-weight:bold;">2002

Additions:

Edgar Filing: ONCOSEC MEDICAL Inc - Form 4

Additions to net assets attributed to:

Contributions:

Participant

\$

4,983,564

\$

4,493,411

Employer matching

1,534,830

1,462,130

Employer profit sharing

Explanation of Responses:

1,583,046

1,183,914

8,101,440

7,139,455

Earnings (losses):

Interest income

90,351

103,134

Dividend income

814,941

Explanation of Responses:

708,409

Net appreciation (depreciation) in the fair value of investments

11,170,258

(6,410,619

)

12,075,550

(5,599,076

)

Other:

Transfer from other plans

364,627

753,952

Total additions

Explanation of Responses:

20,541,617

2,294,331

Deductions:

Deductions from net assets attributed to:

Benefit payments

2,700,954

Explanation of Responses:

2,849,610

Net increase (decrease)

17,840,663

(555,279

)

Net assets available for benefits:

Beginning of year

41,884,109

42,439,388

End of year

Explanation of Responses:

\$

59,724,772

\$

41,884,109

See accompanying notes to the financial statements

**ZEBRA TECHNOLOGIES CORPORATION
PROFIT SHARING AND SAVINGS PLAN**

Notes to the Financial Statements

December 31, 2003 and 2002

(1) Description of Plan

The following description of the Zebra Technologies Corporation Profit Sharing and Savings Plan (the Plan) provides only general information. Participants should refer to the plan agreement for a more complete description of the Plan's provisions.

General

The Plan is a defined contribution plan covering eligible employees of Zebra Technologies Corporation (the Company) subject to certain service requirements. It is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA). Effective March 1, 2001, the Company changed the plan trustee and recordkeeper from Wilmington Trust and AMG, respectively, to T. Rowe Price.

Contributions

Each year, participants may contribute 1% to 15% of eligible compensation on a pretax basis within certain specified limitations. In addition to the Company match of 50% of the participants first 6% of eligible compensation, the Plan permits discretionary profit sharing contributions by the Company which were made by the Company in both 2003 and 2002 as reported in the statements of changes in net assets available for benefits. Employer profit sharing contributions are allocated to participants based upon participant's earnings.

The Plan currently offers 14 mutual funds and Zebra Technologies Corporation common stock as investment options for participants. During 2002, the Plan was amended to permit eligible employees to make additional elective deferrals to the Plan known as "catch-up" contributions, as permitted by the Economic Growth and Tax Relief Reconciliation Act of 2001. Such contributions are excluded from the Company's matching contribution.

Number of Participants

Explanation of Responses:

During 2003, a total of 1,749 employees were eligible to participate in the Plan.

Participant Accounts

Each participant's account is credited with the participant's contribution and allocations of (a) the Company's matching and discretionary profit sharing contributions and (b) plan earnings, and charged with an allocation of administrative expenses. Allocations are based on participant's earnings or account balances, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.

Vesting

Participant contributions, and earnings thereon, vest immediately. Employer matching and discretionary profit sharing contributions, and earnings thereon, vest ratably over five years based on the participant's years of service, as follows:

| | Percent vested | |
|--------------------|---------------------------|--|
| Less than one year | % | |
| One year | 20 | |
| Two years | 40 | |
| Three years | 60 | |
| Four years | 80 | |
| Five years or more | 100 | |

Payment of Benefits

Benefits are recorded when paid. Payments of benefits are in the form of lump sum distributions.

Hardship/Withdrawals

Participants may withdraw funds from their savings contribution account after meeting certain criteria as defined in the Plan. The minimum hardship distribution is \$1,000.

Loans to Participants

Loans are available to plan participants at the prime interest rate (as published by American National Bank of Chicago), under circumstances as described in the Plan. Loans to plan participants are secured by their vested balance and may not exceed the lesser of 50% of their vested balance or \$50,000. Participant loans are repaid through payroll deductions and bear interest at rates ranging from 3.81% to 10.50%.

Termination of the Plan

Although the Company has not expressed any intent to terminate the Plan, it may do so at any time, subject to the provisions of ERISA. In the event of plan termination, participants would become 100% vested in their employer contributions and earnings thereon.

(2) Summary of Significant Accounting Policies

Basis of Presentation

The accompanying financial statements have been prepared on the accrual basis of accounting.

Investment Valuation and Income Recognition

Shares of registered investment companies are valued at quoted market prices, which represent the net asset value of shares held by the Plan at year-end. The Company's common stock is valued at its quoted market price. Participant loans are valued at cost, which approximates fair value. Purchases and sales of securities are recorded on a trade-date basis. The cost of investments is determined on an average cost basis. Dividends are recorded on the ex-dividend date.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of net assets available for benefits and the reported amounts in changes in net assets available for benefits and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates.

(3) Federal Income Taxes

The Plan has received a favorable determination letter from the Internal Revenue Service, dated September 11, 2002, indicating that it is qualified under Section 401(a) of the Internal Revenue Code (IRC) and therefore, the related trust is exempt from tax under Section 501(a) of the IRC.

The Plan has been amended and restated since receiving the determination letter. However, the Plan's trustee and administrator believe that the Plan, as designed, is currently being operated in compliance with the applicable requirements of the IRC.

(4) Administrative Expenses

Edgar Filing: ONCOSEC MEDICAL Inc - Form 4

Amounts forfeited by participants are used to offset administrative expenses of the Plan. To the extent administrative expenses exceed forfeitures such expenses are paid by the Company. The Company paid expenses in the amount of \$5,000 for each of the years ended December 31, 2003 and 2002. It is not the intention of the Company to obtain reimbursements from the Plan for these payments.

(5) Investments

The following table presents the fair value of individual investments that represent 5% or more of the Plan's net assets at December 31, 2003 and 2002, respectively:

| | 2003 | 2002 |
|--|--------------|--------------|
| Pimco Total Return Admin | \$ 5,770,578 | \$ 5,763,850 |
| T. Rowe Price Equity Index Trust | 4,176,793 | 2,706,418 |
| T. Rowe Price Personal Strategy - Balanced | * | 2,134,250 |
| TCW Galileo Select Equities | 7,150,059 | 4,054,084 |
| T. Rowe Price Prime Reserve Fund | 7,284,323 | 6,655,807 |
| Royce Opportunity Fund | 5,191,360 | 2,688,641 |
| T. Rowe Price Dividend Growth Fund | 11,442,298 | 8,496,345 |
| Zebra Stock Fund | 4,468,802 | 2,316,408 |

* Asset does not exceed 5% of Plan's assets at December 31, 2003

During 2003 and 2002, the Plan's investments (including gains and losses on investments bought and sold, as well as held during the year) appreciated (depreciated) in value as follows:

| | 2003 | 2002 |
|--|---------------|----------------|
| Mutual funds | \$ 9,524,441 | \$ (6,504,171) |
| Common stock of Zebra Technologies Corporation | 1,645,817 | 93,552 |
| | \$ 11,170,258 | \$ (6,410,619) |

(6) Transactions with Related Parties

The Zebra Stock Fund at December 31, 2003 and 2002 included 67,332 shares and 40,426 shares, respectively, of common stock of the Company with fair values of \$4,468,802 and \$2,316,408, respectively.

ZEBRA TECHNOLOGIES CORPORATION**PROFIT SHARING AND SAVINGS PLAN**

Schedule H, Line 4i Schedule of Assets (Held at end of year)

December 31, 2003

| (a) | (b) Identity of issuer, borrower, lessor, similar party | (c) Description of investment including maturity date, rate of interest, collateral, par or maturity value | (d) Current value |
|-----|---|--|-------------------|
| | Fidelity Magellan Fund | Mutual fund, 9,951 shares | \$ 972,586 |
| | Pimco Total Return Admin | Mutual fund, 538,803 shares | 5,770,578 |
| | Tradelink Investments | Mutual fund, 107,965 shares | 107,965 |
| * | T. Rowe Price Equity Index Trust | Mutual fund, 135,303 shares | 4,176,793 |
| * | T. Rowe Price Personal Strategy - Income | Mutual fund, 47,993 shares | 665,670 |
| * | T. Rowe Price Personal Strategy - Balanced | Mutual fund, 180,133 shares | 2,975,790 |
| * | T. Rowe Price Personal Strategy - Growth | Mutual fund, 97,094 shares | 1,874,880 |
| | TCW Galileo Select Equities | Mutual fund, 418,867 shares | 7,150,059 |
| | RS Diversified Growth Fund | Mutual fund, 59,365 shares | 1,327,396 |
| * | T. Rowe Price International Stock Fund | Mutual fund 187,429 shares | 2,153,563 |
| * | T. Rowe Price International Discovery | Mutual fund 24,818 shares | 655,194 |
| * | T. Rowe Price Prime Reserve Fund | Mutual fund 7,284,323 shares | 7,284,323 |
| | Royce Opportunity Fund | Mutual fund, 430,818 shares | 5,191,360 |
| * | T. Rowe Price Dividend Growth Fund | Mutual fund, 552,234 shares | 11,442,298 |
| * | Zebra Stock Fund | Common stock of Zebra Technologies Corporation, 67,332 shares | 4,468,802 |
| * | Plan Participants | Participant loans, interest ranging from 3.81% - 10.5%, maturing January 2004 through March 2019 | 1,835,036 |
| | | | \$ 58,052,293 |

* Denotes party-in-interest

See accompanying report of independent registered public accounting firm.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Plan's trustees have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

Zebra Technologies Corporation
Profit Sharing and Savings Plan

June 28, 2004

By: /s/ Edward Kaplan

Edward Kaplan
Plan Trustee